The NLRP3 inflammasome is a potential mechanism and therapeutic target for perioperative neurocognitive disorders

被引:11
|
作者
Li, Jiayue [1 ]
Li, Li [1 ]
He, Jiannan [1 ]
Xu, Jianhong [1 ]
Bao, Fangping [1 ,2 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 4, Int Inst Med, Sch Med,Dept Anesthesiol, Yiwu, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Dept Anesthesiol, Sch Med, Hangzhou, Peoples R China
来源
关键词
perioperative neurocognitive disorders; pyroptosis; NLRP3; inflammasomes; posttranscriptional modifications; targeted protein degradation; nanotechnology; POSTOPERATIVE COGNITIVE DYSFUNCTION; NF-KAPPA-B; MOBILITY GROUP BOX-1; RISK-FACTORS; GASDERMIN D; ACTIVATION; INHIBITION; IMPAIRMENT; PYROPTOSIS; SURGERY;
D O I
10.3389/fnagi.2022.1072003
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Perioperative neurocognitive disorders (PNDs) are frequent complications associated with cognitive impairment during the perioperative period, including acute postoperative delirium and long-lasting postoperative cognitive dysfunction. There are some risk factors for PNDs, such as age, surgical trauma, anesthetics, and the health of the patient, but the underlying mechanism has not been fully elucidated. Pyroptosis is a form of programmed cell death that is mediated by the gasdermin protein and is involved in cognitive dysfunction disorders. The canonical pathway induced by nucleotide oligomerization domain (NOD)-, leucine-rich repeat (LRR)- and pyrin domain-containing protein 3 (NLRP3) inflammasomes contributes to PNDs, which suggests that targeting NLRP3 inflammasomes may be an effective strategy for the treatment of PNDs. Therefore, inhibiting upstream activators and blocking the assembly of the NLRP3 inflammasome may attenuate PNDs. The present review summarizes recent studies and systematically describes the pathogenesis of NLRP3 activation and regulation and potential therapeutics targeting NLRP3 inflammasomes in PNDs patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout
    Szekanecz, Zoltan
    Szamosi, Szilvia
    Kovacs, Gergo E.
    Kocsis, Elek
    Benko, Szilvia
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2019, 670 : 82 - 93
  • [42] NLRP3 Inflammasome as a Therapeutic Target for Atherosclerosis: A Focus on Potassium Outflow
    Jin, Yi-Jing
    An, Zhuo-Yu
    Sun, Zhi-Xuan
    Liu, Xin-Chen
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (08)
  • [43] NLRP3 Inflammasome: An Emerging Therapeutic Target for Alzheimer's Disease
    Tao, Shuqi
    Fan, Wenyuan
    Liu, Jinmeng
    Wang, Tong
    Zheng, Haoning
    Qi, Gaoxiu
    Chen, Yanchun
    Zhang, Haoyun
    Guo, Zhangyu
    Zhou, Fenghua
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 96 (04) : 1383 - 1398
  • [44] The NLRP3 inflammasome: a therapeutic target for inflammation-associated cancers
    Gouravani, Mahdi
    Khalili, Nastaran
    Razi, Sepideh
    Keshavarz-Fathi, Mahsa
    Khalili, Neda
    Rezaei, Nima
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (02) : 175 - 187
  • [45] Mechanism of NLRP3 inflammasome activation
    Sutterwala, Fayyaz S.
    Haasken, Stefanie
    Cassel, Suzanne L.
    YEAR IN IMMUNOLOGY: MYELOID CELLS AND INFLAMMATION, 2014, 1319 : 82 - 95
  • [46] Inhibiting NLRP3 inflammasome with MCC950 ameliorates perioperative neurocognitive disorders, suppressing neuroinflammation in the hippocampus in aged mice
    Fu, Qun
    Li, Jing
    Qiu, Lili
    Ruan, Jiaping
    Mao, Mingjie
    Li, Shuming
    Mao, Qinghong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 82
  • [47] Dysregulation of the NLRP3 Inflammasome in Diabetic Retinopathy and Potential Therapeutic Targets
    Raman, Karanvir S.
    Matsubara, Joanne A.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2022, 30 (02) : 470 - 478
  • [48] NLRP3 inflammasome targeting nanoparticles: A potential therapeutic for the treatment of ischemia
    Murphy, Niamh
    Gerard, Valerie A.
    Gun'ko, Yurii K.
    Lynch, Marina A.
    JOURNAL OF NEUROIMMUNOLOGY, 2012, 253 (1-2) : 108 - 109
  • [49] Therapeutic Potential of Pharmacological Targeting NLRP3 Inflammasome Complex in Cancer
    Tezcan, Gulcin
    Garanina, Ekaterina E.
    Alsaadi, Mohammad
    Gilazieva, Zarema E.
    Martinova, Ekaterina, V
    Markelova, Maria, I
    Arkhipova, Svetlana S.
    Hamza, Shaimaa
    McIntyre, Alan
    Rizvanov, Albert A.
    Khaiboullina, Svetlana F.
    FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [50] NLRP3 inflammasome: a potential therapeutic target to minimize renal ischemia/reperfusion injury during transplantation
    Su, Xiaochen
    Liu, Bin
    Wang, Shangguo
    Wang, Yuxiong
    Zhang, Zehua
    Zhou, Honglan
    Li, Faping
    TRANSPLANT IMMUNOLOGY, 2022, 75